[go: up one dir, main page]

MX2016017038A - Administracion nasal. - Google Patents

Administracion nasal.

Info

Publication number
MX2016017038A
MX2016017038A MX2016017038A MX2016017038A MX2016017038A MX 2016017038 A MX2016017038 A MX 2016017038A MX 2016017038 A MX2016017038 A MX 2016017038A MX 2016017038 A MX2016017038 A MX 2016017038A MX 2016017038 A MX2016017038 A MX 2016017038A
Authority
MX
Mexico
Prior art keywords
nasal
subject
substance
nasal administration
cavity
Prior art date
Application number
MX2016017038A
Other languages
English (en)
Other versions
MX390453B (es
Inventor
Gisle Djupesland Per
A Mahmoud Ramy
Messina John
Original Assignee
Optinose As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/315,132 external-priority patent/US11554229B2/en
Application filed by Optinose As filed Critical Optinose As
Publication of MX2016017038A publication Critical patent/MX2016017038A/es
Publication of MX390453B publication Critical patent/MX390453B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0003Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0091Inhalators mechanically breath-triggered
    • A61M15/0098Activated by exhalation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/08Inhaling devices inserted into the nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001Particle size control
    • A61M11/003Particle size control by passing the aerosol trough sieves or filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • A61M15/0041Details of the piercing or cutting means with movable piercing or cutting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/0007Special media to be introduced, removed or treated introduced into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/02Gases
    • A61M2202/0225Carbon oxides, e.g. Carbon dioxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0468Liquids non-physiological
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un aparato para, o método para suministrar una sustancia, tal como una o más de un triptano, un esteroide nasal o gas de dióxido de carbono, a la cavidad nasal de un sujeto, en particular para el tratamiento de dolores de cabeza, por ejemplo, migraña, o rinosinusitis, por ejemplo rinosinusitis crónica, opcionalmente con pólipos, el método comprende los pasos de adaptar una pieza nasal a una de las fosas nasales del sujeto, suministrar la sustancia a través de la pieza nasal en la región posterior de la cavidad nasal del sujeto.
MX2016017038A 2014-06-25 2015-06-25 Administracion nasal. MX390453B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/315,132 US11554229B2 (en) 2013-03-26 2014-06-25 Nasal administration
PCT/EP2015/064463 WO2015197798A1 (en) 2014-06-25 2015-06-25 Nasal administration

Publications (2)

Publication Number Publication Date
MX2016017038A true MX2016017038A (es) 2017-05-01
MX390453B MX390453B (es) 2025-03-19

Family

ID=53489954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017038A MX390453B (es) 2014-06-25 2015-06-25 Administracion nasal.

Country Status (14)

Country Link
EP (2) EP4233950B1 (es)
JP (2) JP6785227B2 (es)
KR (1) KR102458964B1 (es)
CN (1) CN106470724A (es)
AU (3) AU2015279154A1 (es)
BR (1) BR112016029926A2 (es)
CA (1) CA2953207A1 (es)
ES (1) ES3034743T3 (es)
IL (1) IL249585B (es)
MX (1) MX390453B (es)
RU (1) RU2016152090A (es)
SG (1) SG11201610685XA (es)
WO (1) WO2015197798A1 (es)
ZA (1) ZA201608785B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201713899D0 (en) * 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN108421138A (zh) * 2017-12-25 2018-08-21 宫本海 一种鼻腔雾化吸药器
WO2019222463A1 (en) * 2018-05-16 2019-11-21 Massachusetts Institute Of Technology Methods and apparatus for passive, proportional, valveless gas sampling and delivery
WO2021086811A1 (en) 2019-10-28 2021-05-06 Christopher Page Devices, systems, and methods of monitoring arterial carbon dioxide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
PL203959B1 (pl) 1999-03-03 2009-11-30 Optinose As Nosowe urządzenie do dostarczania substancji do nosowej części dróg oddechowych pacjenta
GB0121568D0 (en) * 2001-09-06 2001-10-24 Optinose As Nasal delivery device
WO2001003645A2 (en) * 1999-07-12 2001-01-18 Capnia, Incorporated Methods and apparatus for relieving headaches, rhinitis and other common ailments
US20070039615A1 (en) * 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
DE60019167T2 (de) * 1999-12-24 2006-05-11 Glaxo Group Ltd., Greenford Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
CA2400375A1 (en) 2000-02-28 2001-09-07 Capnia, Incorporated Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments
ZA200306564B (en) * 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB2403154B (en) * 2002-04-04 2007-01-24 Optinose As Nasal devices
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
GB0320171D0 (en) * 2003-08-28 2003-10-01 Optinose As Delivery devices
ES2668780T3 (es) * 2003-08-29 2018-05-22 Glaxo Group Limited Inhalador de dosificación farmacéutica medida y procedimientos relacionados con el mismo
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
GB0503738D0 (en) * 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0602980D0 (en) * 2006-02-14 2006-03-29 Optinose As Delivery device and method
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB2440316A (en) * 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
GB2448193A (en) * 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB0719299D0 (en) * 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
US20110077272A1 (en) * 2008-02-01 2011-03-31 Vectura Limited Pulmonary formulations of triptans
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
AU2013221302B2 (en) * 2012-02-16 2017-11-23 Capnia, Inc. Gas dispenser with diffusing nosepiece
ES2920802T3 (es) * 2013-03-26 2022-08-09 Optinose As Administración nasal

Also Published As

Publication number Publication date
WO2015197798A1 (en) 2015-12-30
RU2016152090A (ru) 2018-07-27
EP4233950C0 (en) 2025-06-25
CN106470724A (zh) 2017-03-01
JP7090124B2 (ja) 2022-06-23
RU2016152090A3 (es) 2019-02-15
KR20170035919A (ko) 2017-03-31
BR112016029926A2 (pt) 2017-08-22
ES3034743T3 (en) 2025-08-22
EP4233950A1 (en) 2023-08-30
JP6785227B2 (ja) 2020-11-18
ZA201608785B (en) 2019-10-30
MX390453B (es) 2025-03-19
AU2015279154A1 (en) 2017-01-12
IL249585B (en) 2021-04-29
JP2020179191A (ja) 2020-11-05
AU2021215246A1 (en) 2021-09-09
AU2020202029A1 (en) 2020-04-09
IL249585A0 (en) 2017-02-28
EP4233950B1 (en) 2025-06-25
KR102458964B1 (ko) 2022-10-25
JP2017520364A (ja) 2017-07-27
EP3160556A1 (en) 2017-05-03
CA2953207A1 (en) 2015-12-30
SG11201610685XA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
MX2015013774A (es) Administracion nasal.
CL2019001553A1 (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
SA518392270B1 (ar) إنتاج ملاط ثلجي طبي وأنظمة توصيل وطرق
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2016009476A (es) Aparatos para tratamiento de heridas.
MX2016009504A (es) Plasma no termico.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2016017038A (es) Administracion nasal.
EP3113821A4 (fr) Masque facial pour inhalation, adapte a l'administration d'un gaz ou d'une molécule thérapeutique dans le cadre d'un traitement par inhalation, en particulier chez les enfants
CL2017000050A1 (es) Terapia de combinación para el cáncer
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
PE20181166A1 (es) Uso de trientina para el suministro de cobre a un tejido isquemico
GB2553439A (en) Methods for scoring chromosomal instabilities
PH12020550204A1 (en) A non-naturally occurring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using
SG10201810016XA (en) Methods of treating depression using nmda modulators
EP3254704A4 (en) Hydrogen peroxide solution supply apparatus
GT201500056S (es) Aparato para peinar el cabello
MX2016002307A (es) Tratamiento para el cancer.
AR099285A1 (es) Polieteraminas secundarias como inhibidores de hidratos del gas natural, en bajas dosis
AR095638A1 (es) Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario